Citations

Clear

9 citation(s) found for "Zhu, Tong".

USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization
Liu, Jiaqi , Zhu, Qian , Zhang, Yixin , Chen, Yuping , Wang, Kaikai , Lou, Zhenkun , Yuan, Jian

Mayo Clinic

CNS Neuroscience & Therapeutics | April 22, 2024 | Volume: 30 | Issue: 4 | Pages: No page available

10.1111/cns.14711 | PMID 38644551 Get It

AbstractObjectiveTo elucidate the relationship between USP19 and O(6)‐methylguanine‐DNA methyltransferase (MGMT) after temozolomide treatment in glioblastoma (GBM) patients with chemotherapy resistance.MethodsScreening the deubiquitinase pannel and identifying the deubiquitinase directly interacts with and deubiquitination MGMT. Deubiquitination assay to confirm USP19 deubiquitinates MGMT. The colony formation and tumor growth study in xenograft assess USP19 affects the GBM sensitive to TMZ was performed by T98G, LN18, U251, and U87 cell lines. Immunohistochemistry staining and survival analysis were performed to explore how USP19 is correlated to MGMT in GBM clinical management.ResultsUSP19 removes the ubiquitination of MGMT to facilitate the DNA methylation damage repair. Depletion of USP19 results in the glioblastoma cell sensitivity to temozolomide, which can be rescued by overexpressing MGMT. USP19 is overexpressed in glioblastoma patient samples, which positively correlates with the level of MGMT protein and poor prognosis in these patients.ConclusionThe regulation of MGMT ubiquitination by USP19 plays a critical role in DNA methylation damage repair and GBM patients’ temozolomide chemotherapy response.
Three-Dimensional Tendon Scaffold Loaded with TGF-β1 Gene Silencing Plasmid Prevents Tendon Adhesion and Promotes Tendon Repair
Wu, Genbin, Sun, Binbin , Zhao, Chunfeng , Wang, Zhuoying , Teng, Songsong, Yang, Mengkai, Cui, Zhi , Zhu, Guoliang , Yu, Yinxian

Mayo Clinic

ACS Biomaterials Science & Engineering | November 1, 2021 | Volume: 7 | Issue: 12 | Pages: 5739-5748

10.1021/acsbiomaterials.1c00747 | PMID 34723484 Get It

MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Yang, Qifan, Zeng, Xiangyu , Wang, Manxiang , Tu, Xinyi , Wei, Ting , Xie, Wenzhuan , Guo, Qiang , Kloeber, Jake A. , Cao, Yueyu, Guo, Guijie , Zhou, Qin , Huang, Jinzhou , Zhang, Kai , Luo, Kuntian, Kim, Wootae , Hou, Jing , Shi, Yu , Zhu, Qian , Hu, Sheng , Yue, Junqiu , Pi, Guoliang , Kloeber, Jake A , Liu, Li , Kim, Wootae , Zhu, Qian , Wei, Ting , Zeng, Xiangyu , Zhang, Yong , Dong, Shuang , Yang, Bin , Zhang, Chao , Zhao, Fei Linda , Liu, Li , Wang, Mingwei , Yin, Ping , Deng, Min , Chen, Lifeng , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Cancer Discovery | June 7, 2021 | Volume: 11 | Issue: 11 | Pages: 2726-2737

10.1158/2159-8290.cd-20-1500 | PMID 34099454 Get It

Abstract Immune checkpoint blockade (ICB) has revolutionized cancer therapy. However, the response of patients to ICB is difficult to predict. Here, we examined 81 patients with lung cancer under ICB treatment and found that patients with MET amplification were resistant to ICB and had a poor progression-free survival. Tumors with MET amplifications had significantly decreased STING levels and antitumor T-cell infiltration. Furthermore, we performed deep single-cell RNA sequencing on more than 20,000 single immune cells and identified an immunosuppressive signature with increased subsets of XIST- and CD96-positive exhausted natural killer (NK) cells and decreased CD8+ T-cell and NK-cell populations in patients with MET amplification. Mechanistically, we found that oncogenic MET signaling induces phosphorylation of UPF1 and downregulates tumor cell STING expression via modulation of the 3′-UTR length of STING by UPF1. Decreased efficiency of ICB by MET amplification can be overcome by inhibiting MET. Significance: We suggest that the combination of MET inhibitor together with ICB will overcome ICB resistance induced by MET amplification. Our report reveals much-needed information that will benefit the treatment of patients with primary MET amplification or EGFR–tyrosine kinase inhibitor resistant-related MET amplification. This article is highlighted in the In This Issue feature, p. 2659
DOCK7 protects against replication stress by promoting RPA stability on chromatin
Gao, Ming , Guo, Guijie , Huang, Jinzhou , Hou, Xiaonan , Ham, Hyoungjun , Kim, Wootae , Tu, Xinyi , Zhou, Qin , Zhang, Chao , Zhu, Qian , Liu, Jiaqi , Xu, Zhijie , Luo, Kuntian, Weroha, S. John , Billadeau, Daniel D. , Yan, Yuanliang, Weroha, John, Kim, Wootae , Xu, Zhijie , Zhao, Fei , Yan, Yuanliang , Yin, Ping , Deng, Min , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Nucleic Acids Research | March 2, 2021 | Volume: 49 | Issue: 6 | Pages: 3322-3337

10.1093/nar/gkab134 | PMID 33704464 Get It

Abstract RPA is a critical factor for DNA replication and replication stress response. Surprisingly, we found that chromatin RPA stability is tightly regulated. We report that the GDP/GTP exchange factor DOCK7 acts as a critical replication stress regulator to promote RPA stability on chromatin. DOCK7 is phosphorylated by ATR and then recruited by MDC1 to the chromatin and replication fork during replication stress. DOCK7-mediated Rac1/Cdc42 activation leads to the activation of PAK1, which subsequently phosphorylates RPA1 at S135 and T180 to stabilize chromatin-loaded RPA1 and ensure proper replication stress response. Moreover, DOCK7 is overexpressed in ovarian cancer and depleting DOCK7 sensitizes cancer cells to camptothecin. Taken together, our results highlight a novel role for DOCK7 in regulation of the replication stress response and highlight potential therapeutic targets to overcome chemoresistance in cancer.
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining
Zhou, Qin , Howard, Michelle E. , Tu, Xinyi , Zhu, Qian , Denbeigh, Janet M. , Remmes, Nicholas B. , Herman, Michael , Beltran, Chris , Greipp, Patricia T. , Wang, Liewei , Johnson, Neil , Mutter, Robert W. , Herman, Michael G., Beltran, Chris J., Boughey, JC , Beltran, Chris J , Greipp, Patricia T , Yuan, Jian , Boughey, Judy C. , Goetz, Matthew P. , Sarkaria, Jann N. , Lou, Zhenkun

Mayo Clinic

Cancer Research | February 17, 2021 | Volume: 81 | Issue: 12 | Pages: 3333-3346

10.1158/0008-5472.can-20-2960 | PMID 33597272 Get It

Abstract Proton Bragg peak irradiation has a higher ionizing density than conventional photon irradiation or the entrance of the proton beam profile. Whether targeting the DNA damage response (DDR) could enhance vulnerability to the distinct pattern of damage induced by proton Bragg peak irradiation is currently unknown. Here, we performed genetic or pharmacologic manipulation of key DDR elements and evaluated DNA damage signaling, DNA repair, and tumor control in cell lines and xenografts treated with the same physical dose across a radiotherapy linear energy transfer spectrum. Radiotherapy consisted of 6 MV photons and the entrance beam or Bragg peak of a 76.8 MeV spot scanning proton beam. More complex DNA double-strand breaks (DSB) induced by Bragg peak proton irradiation preferentially underwent resection and engaged homologous recombination (HR) machinery. Unexpectedly, the ataxia-telangiectasia mutated (ATM) inhibitor, AZD0156, but not an inhibitor of ATM and Rad3-related, rendered cells hypersensitive to more densely ionizing proton Bragg peak irradiation. ATM inhibition blocked resection and shunted more DSBs to processing by toxic ligation through nonhomologous end-joining, whereas loss of DNA ligation via XRCC4 or Lig4 knockdown rescued resection and abolished the enhanced Bragg peak cell killing. Proton Bragg peak monotherapy selectively sensitized cell lines and tumor xenografts with inherent HR defects, and the repair defect induced by ATM inhibitor coadministration showed enhanced efficacy in HR-proficient models. In summary, inherent defects in HR or administration of an ATM inhibitor in HR-proficient tumors selectively enhances the relative biological effectiveness of proton Bragg peak irradiation. Significance: Coadministration of an ATM inhibitor rewires DNA repair machinery to render cancer cells uniquely hypersensitive to DNA damage induced by the proton Bragg peak, which is characterized by higher density ionization. See related commentary by Nickoloff, p. 3156
The deubiquitinase USP36 Regulates DNA replication stress and confers therapeutic resistance through PrimPol stabilization
Xu, Zhijie , Huang, Jinzhou , Guo, Guijie , Gao, Ming , Kim, Wootae , Zeng, Xiangyu , Kloeber, Jake A. , Zhu, Qian , Luo, Kuntian, Yan, Yuanliang, Kloeber, Jake A , Kim, Wootae , Xu, Zhijie , Zeng, Xiangyu , Yan, Yuanliang , Zhao, Fei , Lou, Zhenkun , Guo, Guijie

Mayo Clinic

Nucleic Acids Research | October 29, 2020 | Volume: 48 | Issue: 22 | Pages: 12711-12726

10.1093/nar/gkaa1090 | PMID 33237263 Get It

Abstract PrimPol has been recently identified as a DNA damage tolerant polymerase that plays an important role in replication stress response. However, the regulatory mechanisms of PrimPol are not well defined. In this study, we identify that the deubiquitinase USP36 interferes with degradation of PrimPol to regulate the replication stress response. Mechanistically, USP36 is deubiquitinated following DNA replication stress, which in turn facilitates its upregulation and interaction with PrimPol. USP36 deubiquitinates K29-linked polyubiquitination of PrimPol and increases its protein stability. Depletion of USP36 results in replication stress-related defects and elevates cell sensitivity to DNA-damage agents, such as cisplatin and olaparib. Moreover, USP36 expression positively correlates with the level of PrimPol protein and poor prognosis in patient samples. These findings indicate that the regulation of PrimPol K29-linked ubiquitination by USP36 plays a critical role in DNA replication stress and chemotherapy response.
Restless legs syndrome following the use of ziprasidone: a case report
Zhu, Cuizhen , Bi, Ran , Hu, Yuliang , Zhu, Daomin , Isaacson, Brian, Li, Qingwei , Lin, Yezhe , Zhou, Hui , Isaacson, Brian

Mayo Clinic

General Psychiatry | March 12, 2020 | Volume: 33 | Issue: 2 | Pages: No page available

10.1136/gpsych-2019-100112 | PMID 32215360 Get It

Restless legs syndrome (RLS) is a common sleep‐related movement disorder characterised by an uncomfortable urge to move the legs that occurs during periods of inactivity. Although there have been many case reports on antipsychotic‐induced RLS, ziprasidone has never been reported as a cause of RLS. We present a case of a female patient with schizophrenia who presented with symptoms of RLS following the administration of high doses of ziprasidone added to quetiapine and valproate. The patient’s symptoms of RLS occurred following the administration and titration of ziprasidone to 160 mg, and were relieved upon reducing the dose to 120 mg/day. Other potential causative medications and differential diagnoses that could have caused similar symptoms were excluded. Clinicians should be aware of the potential for ziprasidone‐induced RLS. Dopamine and serotonin interaction could be the mechanism underlying ziprasidone‐induced RLS.
Is Exposure to Famine in Childhood and Economic Development in Adulthood Associated With Diabetes?
Wang, Ningjian , Wang, Xiaojin , Han, Bing , Li, Qin , Chen, Yi , Chen, Yingchao , Xia, Fangzhen , Cang, Zhen, Zhu, Chaoxia , Lu, Meng , Lin, Dongping, Wang, Bingshun , Jensen, Michael D. , Lu, Yingli , Zhu, Chunfang, Meng, Ying , Chen, Chi , Zhu, Chunfang , Meng, Ying

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | October 28, 2015 | Volume: 100 | Issue: 12 | Pages: 4514-4523

10.1210/jc.2015-2750 | PMID 26509871 Get It

Different Stages of White Matter Changes in the Original HDLS Family Revealed by Advanced MRI Techniques
Sundal, Christina , Jönsson, Lars , Ljungberg, Maria , Zhong, Jianhui , Tian, Wei , Zhu, Tong , Lindén, Thomas , Börjesson‐Hanson, Anne, Andersen, Oluf , Ekholm, Sven

Mayo Clinic

Journal of Neuroimaging | June 10, 2013 | Volume: 24 | Issue: 5 | Pages: 444-452

10.1111/jon.12037 | PMID 23751174 Get It

ABSTRACTBACKGROUNDThe temporal evolution of white matter (WM) changes on MR examinations in hereditary diffuse leukoencephalopathy with spheroids (HDLS) is largely unknown. Our purpose was to investigate the evolution of these WM changes with diffusion weighted/tensor imaging (DWI/DTI) and MR Spectroscopy (MRS).METHODSA newly diagnosed patient with HDLS from the original Swedish family was followed prospectively with 5 MRI as well as DWI/DTI and MRS examinations during 16 months.RESULTSThe DTI eigenvalues demonstrated changes that suggested early myelin and axonal disturbances in the normal appearing WM (NAWM). DWI/DTI showed a rim of decreased diffusion progressively expanding through the WM from the initial frontal periventricular zones, and indicated complete destruction of axons and myelin in the area behind the front. MRS findings were suggestive of axonal destruction in the NAWM.CONCLUSIONWe describe HDLS changes in three temporal stages of development corresponding to lesions outside, in the vicinity of, and behind a characteristic rim centrifugally progressing from the ventricular horns. The axonal disturbances indicated by MRS changes in the NAWM support a primary axonal degeneration, as proposed in the original HDLS report, rather than axonal degeneration secondary to demyelination. These findings could help in differential diagnosis of HDLS.